Score Breakdown
Trash.
Ultragenyx is a deeply unprofitable rare disease biotech trading at 3.8x trailing revenue with negative shareholders' equity, $1.1B in royalty liabilities functioning as high-cost debt, and a cash runway of approximately 10 months. The investment case is entirely binary: it depends on two gene therapy PDUFA decisions in Aug/Sep 2026 and a Phase 3 Angelman readout, any of which could fail given the company's track record of CRLs and the recent setrusumab Phase 3 failure. Even under optimistic approval scenarios, the small patient populations and payer friction for gene therapies create a long monetization timeline. The 2027 profitability target requires heroic R&D cuts and successful launches simultaneously. With 13% short interest, 4.5% annual dilution, insider selling, and a securities fraud lawsuit, the risk/reward skews negatively. Analyst targets averaging $50 seem detached from the deteriorating financial reality, though I acknowledge significant optionality if both gene therapies are approved and GTX-102 succeeds.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Minimal.
Neutral.
Clock is ticking.
Significant shorts.
Below average.
🐻 Why Bears Hate It
The bear thesis centers on a persistent and widening loss profile, with a trailing twelve-month (LTM) net loss of $609 million and negative shareholders' equity (Simply Wall St). Skeptics argue that despite top-line growth, the path to GAAP profitability by 2027 is a 'high bar' due to massive R&D spending and the inherent binary risks of its gene therapy pipeline. With $1.25 billion in debt and a depleting cash position ($680M at year-end 2025), the company faces high dilution risk if upcoming late-stage readouts for DTX401 or GTX-102 underperform (Seeking Alpha).
🔍 What's In The SEC Filings
The company is fundamentally insolvent on a GAAP basis, surviving solely by selling off future royalty streams and aggressive equity issuance while core product sales shrink.
Technical GAAP Insolvency and Shareholder Deficit
“Total stockholders' equity (deficit) [-236, -80]”
The company's liabilities now exceed its assets by $236 million, a sharp deterioration from a deficit of $80 million just three months prior, signaling a total collapse of the balance sheet.
Predatory Royalty Liabilities Functioning as High-Interest Debt
“Liabilities for sales of future royalties [1128, 1147]”
The company has over $1.2 billion in 'liabilities for sales of future royalties' which carry effective interest rates as high as 9.2%. This is debt in all but name, collateralized by the company's only viable income streams.
Significant Contraction in Core Product Sales
“Crysvita $46 [in 2026] $55 [in 2025]”
Sales for the company's flagship product, Crysvita, dropped 16.3% year-over-year, suggesting either market saturation, loss of market share, or a fundamental failure in commercialization.
Massive Subsequent Event Equity Grants
“During April 2026, the Company granted 1.5 million options, 3.6 million restricted stock units, or RSUs, and 0.9 million performance stock units”
In the month immediately following the quarter, management granted 6 million share equivalents, representing approximately 6% of the total shares outstanding in a single dilutive event.
The $1.2B in royalty liabilities should be treated as senior debt when calculating enterprise value. Given the negative equity and $185M quarterly net loss, the company's intrinsic value is highly dependent on a speculative 'liquidation' of its remaining pipeline or a massive capital raise that will wipe out current common shareholders.
A 10% workforce reduction was implemented in Q1 2026, resulting in a $30M restructuring charge, primarily impacting R&D. Furthermore, the CLO and a Director adopted 10b5-1 trading plans in March 2026, potentially signaling an exit strategy.
At the current burn rate, this company will need to raise money or die.